Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion

Kathleen M Andersen, Ayano Kelly, Anne Lyddiatt, Clifton O Bingham, Vivian P Bykerk, Adena Batterman, Joan Westreich, Michelle K Jones, Marita Cross, Peter Brooks, Lyn March, Beverley Shea, Peter Tugwell, Lee S Simon, Robin Christensen, Susan J Bartlett

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.

METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.

RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.

CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

OriginalsprogEngelsk
TidsskriftJournal of Rheumatology
Vol/bind46
Udgave nummer9
Sider (fra-til)1168-1172
ISSN0315-162X
DOI
StatusUdgivet - sep. 2019

Fingeraftryk

Antirheumatic Agents
Rheumatology
Focus Groups
Safety
Life Change Events
Rheumatic Diseases
Drug-Related Side Effects and Adverse Reactions
Outcome Assessment (Health Care)
Pharmaceutical Preparations

Citer dette

Andersen, Kathleen M ; Kelly, Ayano ; Lyddiatt, Anne ; Bingham, Clifton O ; Bykerk, Vivian P ; Batterman, Adena ; Westreich, Joan ; Jones, Michelle K ; Cross, Marita ; Brooks, Peter ; March, Lyn ; Shea, Beverley ; Tugwell, Peter ; Simon, Lee S ; Christensen, Robin ; Bartlett, Susan J. / Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials : Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. I: Journal of Rheumatology. 2019 ; Bind 46, Nr. 9. s. 1168-1172.
@article{248220597ac944f0974144a736cb3d72,
title = "Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion",
abstract = "OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.",
author = "Andersen, {Kathleen M} and Ayano Kelly and Anne Lyddiatt and Bingham, {Clifton O} and Bykerk, {Vivian P} and Adena Batterman and Joan Westreich and Jones, {Michelle K} and Marita Cross and Peter Brooks and Lyn March and Beverley Shea and Peter Tugwell and Simon, {Lee S} and Robin Christensen and Bartlett, {Susan J}",
year = "2019",
month = "9",
doi = "10.3899/jrheum.181185",
language = "English",
volume = "46",
pages = "1168--1172",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology Publishing Co. Ltd.",
number = "9",

}

Andersen, KM, Kelly, A, Lyddiatt, A, Bingham, CO, Bykerk, VP, Batterman, A, Westreich, J, Jones, MK, Cross, M, Brooks, P, March, L, Shea, B, Tugwell, P, Simon, LS, Christensen, R & Bartlett, SJ 2019, 'Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion', Journal of Rheumatology, bind 46, nr. 9, s. 1168-1172. https://doi.org/10.3899/jrheum.181185

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials : Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. / Andersen, Kathleen M; Kelly, Ayano; Lyddiatt, Anne; Bingham, Clifton O; Bykerk, Vivian P; Batterman, Adena; Westreich, Joan; Jones, Michelle K; Cross, Marita; Brooks, Peter; March, Lyn; Shea, Beverley; Tugwell, Peter; Simon, Lee S; Christensen, Robin; Bartlett, Susan J.

I: Journal of Rheumatology, Bind 46, Nr. 9, 09.2019, s. 1168-1172.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials

T2 - Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion

AU - Andersen, Kathleen M

AU - Kelly, Ayano

AU - Lyddiatt, Anne

AU - Bingham, Clifton O

AU - Bykerk, Vivian P

AU - Batterman, Adena

AU - Westreich, Joan

AU - Jones, Michelle K

AU - Cross, Marita

AU - Brooks, Peter

AU - March, Lyn

AU - Shea, Beverley

AU - Tugwell, Peter

AU - Simon, Lee S

AU - Christensen, Robin

AU - Bartlett, Susan J

PY - 2019/9

Y1 - 2019/9

N2 - OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

AB - OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

U2 - 10.3899/jrheum.181185

DO - 10.3899/jrheum.181185

M3 - Journal article

C2 - 30770516

VL - 46

SP - 1168

EP - 1172

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 9

ER -